3,4-dihydro-4-methyl-6-nitro-1,4-benzoxazine | 120711-82-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 3,4-dihydro-4-methyl-6-nitro-1,4-benzoxazine
• 英文别名: 4-methyl-6-nitro-3,4-dihydro-2H-1,4-benzoxazine；4-methyl-6-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine；4-methyl-6-nitro-3,4-dihydro-2H-benzo[1,4]oxazine；1-methyl-7-nitro-3,4-dihydro-2H-benzo[1,4]oxazine；4-methyl-6-nitro-2,3-dihydro-1,4-benzoxazine
• CAS: 120711-82-2
• 化学式: C₉H₁₀N₂O₃
• 分子量: 194.19
• InChiKey: FJSDSFYITDCJDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-4-methyl-6-nitro-1,4-benzoxazine 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 以89%的产率得到3,4-dihydro-4-methyl-6-amino-1,4-benzoxazine
  参考文献：
  名称：

  [EN] PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS
  [FR] DÉRIVÉS DE PURINE CONVENANT COMME INHIBITEURS DE HSP90

  摘要：

  本申请提供所示公式的取代嘌呤衍生物及相关化合物。这些化合物作为HSP90抑制剂具有用途，因此可用于治疗相关疾病。（公式）Z1-Z3、Xa-Xc、X2、X4、Y和R的定义见说明书。

  公开号：

  WO2011044394A1
• 作为产物：
  描述：

  3,4-二氢-6-硝基-1,4-苯并恶嗪-4-甲醛 在 盐酸 、 硼烷四氢呋喃络合物 作用下， 生成 3,4-dihydro-4-methyl-6-nitro-1,4-benzoxazine
  参考文献：
  名称：

  Heteroaromatic analogs of the .alpha.2-adrenoreceptor partial agonist clonidine

  摘要：

  A 1,4-dioxane analogue (1) of the alpha 2-adrenoreceptor partial agonist clonidine (2) has previously been shown to possess an interesting but complex pharmacological profile. In this study, from a series of other heterocyclic analogues of clonidine, the 1,4-oxazines 6 and 12 were found to resemble 1 in that they are partial alpha 2-agonists in the periphery and are excluded from the central nervous system. However, when given directly into the brain, they behave as pure alpha 2-antagonists.

  DOI：

  10.1021/jm00127a037

文献信息

• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors
  申请人：Allergan Sales, Inc.

  公开号：US20020156076A1

  公开（公告）日：2002-10-24

  Compounds having adrenergic activity which are a selective agonists for one or both of the &agr; 2B and &agr; 2c adrenoceptor receptor subtypes in preference to the &agr; 2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having the formula 1 wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R 1 , wherein R 1 is H or lower alkyl, but R 1 is absent when the bond between X and the ring represented by 2 is a double bond; Y is O, N, S, (CR 1 2 ) y , wherein y is an integer of from 1 to 3, —CH═CH— or —Y 1 CH 2 —, wherein Y 1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R 2 , R 3 or R 4 is bound to an unsaturated carbon atom and x is 2 when R 2 , R 3 or R 4 is bonded to a saturated carbon atom; R 2 is H, lower alkyl, halogen, hydroxy, lower alkoxy, lower alkenyl, acyl or lower alkynyl, or, when attached to a saturated carbon atom, R 2 may be oxo; R 3 and R 4 are, each, H, lower alkyl, halogen, lower alkenyl, acyl, lower alkynyl, aryl, heteroaryl, or sub stituted aryl or heteroaryl, wherein said substituent is halogen, lower alkyl, lower alkoxy, lower alkenyl, acyl, lower alkynyl, nitro, cyano, trifluoromethyl, hydroxy, or phenyl or, together, are —(C(R 2 )x)z—; —Y 1 (C(R 2 )x)z′—; —Y 1 (C(R 2 )x)y Y 1 —; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—(C(R 2 )x)— and —Y 1 —(C(R 2 )x)—Y 1 —(C(R 2 )x)— wherein z is an integer of from 3 to 5, z′ is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素活性的化合物，是选择性激动剂，优先作用于α2B和α2C肾上腺素受体亚型中的一个或两个，而不是α2A肾上腺素受体亚型；所述活性化合物从以下化合物组中选择，其具有下列式1的化合物，其中虚线代表可选键，但两个双键不能共用一个碳原子；R为H或较低的烷基；X为S或C(H)R1，其中R1为H或较低的烷基，但当X与由2表示的环之间的键为双键时，R1不存在；Y为O、N、S、(CR12)y，其中y为1至3的整数，—CH2CH—或—Y1CH2—，其中Y1为O、N或S；x为1或2的整数，当R2、R3或R4与不饱和碳原子结合时，x为1，当R2、R3或R4与饱和碳原子结合时，x为2；R2为H、较低的烷基、卤素、羟基、较低的烷氧基、较低的烯基、酰基或较低的炔基，或者当连接到饱和碳原子时，R2可能为酮基；R3和R4分别为H、较低的烷基、卤素、较低的烯基、酰基、较低的炔基、芳基、杂环芳基或取代的芳基或杂环芳基，其中所述取代基为卤素、较低的烷基、较低的烷氧基、较低的烯基、酰基、较低的炔基、硝基、氰基、三氟甲基、羟基或苯基，或者共同为—(C(R2)x)z—；—Y1(C(R2)x)z′—；—Y1(C(R2)x)y Y1—；—(C(R2)x)—Y1—(C(R2)x)—；—(C(R2)x)—Y1—(C(R2)x)—(C(R2)x)—和—Y1—(C(R2)x)—Y1—(C(R2)x)—其中z为3至5的整数，z′为2至4的整数，x和y如上所定义，而且这些二价基团的每一端都可以连接到R3或R4中的任一端，形成一个紧凑的环结构，所形成的环可以是完全不饱和的、部分不饱和的或完全饱和的；并且适用于治疗肌肉痉挛，包括过度活跃的小便、腹泻、利尿、戒断综合征、包括神经病理性疼痛、神经退行性疾病、记忆和认知缺陷、精神病，包括躁狂障碍和焦虑、高血压、心肌缺血、充血性心力衰竭和鼻塞，无镇静或心血管副作用。
• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
  申请人：ALLERGAN SALES, INC.

  公开号：US20030023098A1

  公开（公告）日：2003-01-30

  Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.

  用于治疗疼痛、特别是慢性疼痛、青光眼或高眼压的方法和化合物，具有减少心血管或镇静副作用。还包括制备和使用这些化合物的方法。
• Dual SNAr reaction in activated ortho-halonitrobenzene: direct synthesis of substituted 1,2,3,4-tetrahydroquinoxalines, 2,3-dihydro-1,4-benzoxazines, and 1,4-benzodioxines
  作者：Mahesh S. Deshmukh、Biswajit Das、Nidhi Jain

  DOI：10.1039/c3ra44386h

  日期：——

  An unprecedented one-pot synthesis of substituted 1,2,3,4-tetrahydroquinoxalines, 2,3-dihydro-1,4-benzoxazines, and 1,4-benzodioxines from activated ortho-halonitrobenzenes has been accomplished by dual nucleophilic aromatic substitution (SNAr) of halogen followed by substitution of the nitro group by secondary diamines, secondary amino alcohols, and diols respectively.

  通过对氯取代的氮杂环合成，成功实现了一种前所未有的一锅法合成取代的1,2,3,4-四氢喹喱啉、2,3-二氢-1,4-苯并噁唑和1,4-苯并二恶烷，反应由双亲核芳香取代（SNAr）卤素开始，随后分别用二级胺、二级氨基醇和二醇替代硝基。
• Hsp90 Inhibitors
  申请人：Chiosis Gabriela

  公开号：US20120208806A1

  公开（公告）日：2012-08-16

  The present application provides compounds useful in the inhibition of Hsp90, and hence in the treatment of disease.

  本申请提供了一些化合物，可用于抑制Hsp90，并因此用于治疗疾病。
• Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
  申请人：Allergan, Inc.

  公开号：EP1413576A2

  公开（公告）日：2004-04-28

  Coumpounds having adrenergic activity which are selective agonists for one or both of the α2B and α2C adrenoceptor receptor subtypes in preference to the α2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having formula (I) wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R1, wherein R1 is H or lower alkyl, but R1 is absent when the bond between X and the ring represented by formula (a) is a double bond; Y is O, N, S, (CR12)y, wherein y is an integer of from 1 to 3, -CH=CH- or -Y1CH2-, wherein Y1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R2, R3 or R4 is bound to a saturated carbon atom and x is 2 when R2, R3 or R4 is bound to a saturated carbon atom; R2 is H, lower alkyl, halogen, hydroxy or lower alkoxy, or, when attached to a saturated carbon atom, R2 may be oxo; R3 and R4 are, each, H, lower alkyl, hydroxy, lower alkoxy, or phenyl or, together, are -(C(R2)x)z-; -Y1(C(R2)x)z'-; -Y1(C(R2)x)yY1-; -(C(R2)x)-Y1-(C(R2)x)-; -(C(R2)x)-Y1-(C(R2)x)-(C(R2)x)- and -Y1-(C(R2)x)-Y1-(C(R2)x)- wherein z is an integer of from 3 to 5, z' is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素能活性的偶联化合物，是一种或两种 α2B和α2C肾上腺素受体亚型的选择性激动剂，优于α2A肾上腺素受体亚型；活性化合物选自由式(I)组成的化合物组，其中虚线代表任选键，但两个双键不得共用一个碳原子；R是H或低级烷基；X 是 S 或 C(H)R1，其中 R1 是 H 或低级烷基，但当 X 与式 (a) 所代表的环之间的键是双键时，R1 不存在； Y 是 O、N、S、(CR12)y（其中 y 是 1 至 3 的整数）、-CH=CH- 或 -Y1CH2-，其中 Y1 是 O、N 或 S；x 是 1 或 2 的整数，其中，当 R2、R3 或 R4 与饱和碳原子结合时，x 为 1，当 R2、R3 或 R4 与饱和碳原子结合时，x 为 2；R2 是 H、低级烷基、卤素、羟基或低级烷氧基，或者，当与饱和碳原子连接时，R2 可以是氧代；R3 和 R4 分别是 H、低级烷基、羟基、低级烷氧基或苯基，或者合在一起是-(C(R2)x)z-；-Y1(C(R2)x)z'-；-Y1(C(R2)x)yY1-；-(C(R2)x)-Y1-(C(R2)x)-；-(C(R2)x)-Y1-(C(R2)x)-(C(R2)x)-和-Y1-(C(R2)x)-Y1-(C(R2)x)- 其中 z 是 3 至 5 的整数，z'是 2 至 4 的整数，x 和 y 如上文所定义、此外，这些二价分子的任何一端都可以连接到 R3 或 R4 上，形成缩合环结构，所形成的环可以是完全不饱和、部分不饱和或完全饱和的；可用于治疗肌肉痉挛（包括排尿亢进）、腹泻、利尿、戒断综合征、疼痛（包括神经性疼痛）、神经退行性疾病、记忆和认知障碍、精神病（包括躁狂症和焦虑症）、高血压、心脏缺血、充血性心力衰竭和鼻塞，且无镇静或心血管副作用。